SS 31 Peptide: A Breakthrough in Mitochondrial Therapy

SS 31 peptide, known as Bendavia or MTP-131, is a breakthrough in mitochondrial-targeted therapeutics, designed to mitigate oxidative stress and maintain mitochondrial function. By binding to cardiolipin in the inner mitochondrial membrane, it stabilizes mitochondria, reducing reactive oxygen species and preventing dysfunction. This offers potential treatments for neurodegenerative diseases, heart conditions, and muscle disorders. Ongoing research highlights its promise in addressing various conditions linked to mitochondrial health, positioning SS 31 as a significant therapeutic advancement.

SS-31 Peptide: A Breakthrough in Mitochondrial Medicine

SS 31 peptide, also known as elamipretide, targets mitochondria to combat dysfunction by stabilizing cardiolipin on the inner membrane. This peptide boosts electron transport and curtails reactive oxygen species, enhancing energy production and reducing oxidative stress. It’s being studied for treating mitochondrial-related diseases like cardiovascular and neurodegenerative disorders.

SS 31 Peptide: A Breakthrough in Mitochondrial Research

Ss 31 peptide, or elamipretide, is a tetrapeptide designed to target the inner mitochondrial membrane, stabilizing cardiolipin to enhance mitochondrial function. By improving the electron transport chain and reducing oxidative stress, it bolsters mitochondrial bioenergetics and cell health, showing promise in treating conditions like Barth syndrome and neurodegenerative disorders.

Select Wishlist

    Left Menu Icon
    Your Cart